Overview
- Research presented Tuesday at the European Congress on Obesity found that people who lost more weight after starting GLP-1 drugs had lower rates of osteoarthritis, chronic kidney disease, obstructive sleep apnea, and, to a lesser extent, heart failure.
- An analysis of 89,718 U.S. patients showed that losing at least 15% of body mass index was associated with 37% lower osteoarthritis risk, 30% lower chronic kidney disease risk, 69% lower sleep apnea risk, and a 32% lower heart failure risk that did not reach statistical significance.
- The same U.S. dataset showed real-world use is hard to sustain as roughly half of patients stopped GLP-1 treatment within a year, which could limit how long health gains last.
- A separate U.K. NHS cohort run by Oviva reported an average 12.4% weight loss at nine months, with sick days down about 45% and face-to-face GP visits down about 43%, alongside sharp drops in remote consultations.
- Oviva estimated that scaling the program could free nearly 10 million GP appointments and save about £364 million a year, though researchers stressed these modeled figures and all associations are early and observational, with possible drivers including less pain, better mood, and lower inflammation.